SynthesisBMC pulmonary medicine2025
Safety and efficacy of pulmonary surfactant therapy for acute respiratory distress syndrome in children: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lung Ultrasound-Guided Surfactant Therapy in Neonatal Pneumothorax and Pulmonary Hemorrhage: Pathophysiology, Diagnostic Ultrasonography, and Emerging Clinical Approaches.Children (Basel, Switzerland) · 2026Review
- Surfactant therapy for the treatment of acute respiratory distress syndrome: time to revisit?Journal of applied physiology (Bethesda, Md. : 1985) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePulmonary surfactants (PSs) are generally known to be effective in treating newborns with acute respiratory distress syndrome (ARDS). However, their effectiveness in children remains controversial. The purpose of the current systematic review and meta-analysis was to assess the effectiveness and safety of PS in children.
methodsA comprehensive search of the PubMed, EMBASE, Cochrane, CNKI, and Wanfang databases was conducted to identify publications up to December 2024. Only multicenter, randomized controlled trials involving children aged between 1 month and 18 years with acute lung injury or ARDS were included. The intervention group received PS treatment, whereas the control group received a placebo. The primary outcome measure was mortality rate, and secondary outcomes included days without mechanical ventilation, duration of mechanical ventilation, incidence of adverse events, and oxygenation index (OI).
resultsSeven articles met the inclusion criteria. The use of PS was associated with a significant reduction in the mortality rate (relative risk [RR] = 1.50, 95% confidence interval [CI] = 1.11-2.01, p = 0.008). In terms of secondary outcomes, there was an increase in the number of days without mechanical ventilation (mean difference = 1.20, 95% CI = 0.24-2.15, p = 0.01) and a lower incidence of adverse events (RR = 1.76, 95% CI = 1.14 to 2.71, p = 0.01) in the intervention group than in the control group, with no significant difference in mechanical ventilation duration (MD = -1.06, 95% CI = -3.47 to -1.35, p = 0.39) or OI (MD = -0.65, 95% CI = -3.48 to -2.19, p = 0.66).
conclusionPS treatment was associated with a reduction in the mortality rate and incidence of adverse events in critically ill children with ARDS; however, the clinical impact of PS treatment warrants further research.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.